Introduction
It is common practise for pharmaceutical companies to have their medicines manufactured - either whole or in part - through contract manufacturers. In such arrangements, the actual manufacturer obtains a license (in Form 25 or 28 under the Drugs and Cosmetics Rules, 1945 ("DCR"), depending on the product).The company's name is printed on the labelling as 'Marketer' in addition to the details of the manufacturer. Typically, the manufacturer is responsible for compliance with the requirements of the Drugs and Cosmetics Act, 1940, ("DCA") (labelling, quality etc.) while the marketer / distributor provides the artwork and other specifications. Further, the marketer obtains a wholesale license for their facilities rather than a repackaging license or loan licenses (in Forms 25-A or 28-A).
However, these arrangements have come under scrutiny from the authorities. In particular in the case of
Recent Amendments
Per amendments to the DCR (in
Existing Liability of 'Marketers'
As a corollary to being granted legal recognition, drug 'marketers' ought to be mindful of the various statutes that typically govern the manufacture / sale of medicines outside of the DCA.
First, while such marketers may have been liable under consumer law even under the old regime, they can expect greater scrutiny under the Consumer Protection Act, 2019 where they may face claims for unfair trade practices, false or misleading advertisements, or product liability (given that such marketers typically exercise substantial control over the design / manufacture of the product). Such claims may result in refunds, compensation, damages, the issue of corrective advertisements etc.
Second, under the Drugs (Price Control) Order, 2013 ("DPCO") marketers were already included within the definition of 'manufacturers'. Under the DPCO, price control takes two broad forms: (i) where the Government fixes the ceiling pricing of notified drugs, specified in the National List of Essential Medicines ("NLEM") which are included in the First Schedule to the DPCO; and (ii) where the government restricts an increase in price by more than 10% in any 12 month period for notified drugs (but not included in the First Schedule). Non-compliance may result in the Government ordering a reduction of prices with penalties.
Third, marketers would need to adhere to advertising restrictions under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 which impose a blanket ban on advertising of prescription medicines, prohibit the advertising of medicines used in the treatment of certain specified diseases, and penalise false or misleading advertisements, through fines and / or imprisonment.
Conclusion
Speaking strictly with regard to the amendment - drug 'marketers' would need to enter into written agreements to ensure that their operations do not face hurdles. Additionally, the amendments do not address the question of past non-compliance and whether authorities would pursue action against companies for such non-compliance.
The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at legalalerts@khaitanco.com
Mr
Khaitan & Co
One Indiabulls Centre
13th Floor, Tower 1
841 Senapati Bapat Marg
400 013
Tel: 226636 5000
Fax: 226636 5050
E-mail: bdo@khaitanco.com, Nilanjan.ghose@khaitanco.com
URL: www.khaitanco.com
© Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source